Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ERAS-601

Small molecule · Inhibitor of Tyrosine-protein phosphatase non-receptor type 11 (SHP2) (PTPN11) · developed by Erasca

Phase 1/2 Most advanced trial (none active)
ERAS Developer
1 Registered trials

What is ERAS-601?

ERAS-601 is an orally bioavailable inhibitor of the SHP2 phosphatase (PTPN11) that binds SHP2 and blocks its activity, suppressing MAPK signaling in SHP2-dependent tumor cells. It is being studied in advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Tyrosine-protein phosphatase non-receptor type 11 (SHP2) (PTPN11)
Mechanism
Inhibitor of Tyrosine-protein phosphatase non-receptor type 11 (SHP2) (PTPN11)
Pathways
Ras-Raf-MEK-ERK (MAPK) signaling, PD-1 signal transduction
Therapy area
Oncology
Developer
Erasca, Inc. (ERAS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04866134 Phase 1/2 Advanced or Metastatic Solid Tumors Completed ERAS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumors

Other drugs acting on PTPN11

More from Erasca

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the ERAS page.

Follow ERAS, the company behind ERAS-601

See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ERAS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.